The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk
A Nationwide Cohort Study

Wen-Kuan Huang, MD, Hung-Chih Hsu, MD, Jia-Rou Liu, MS, Tsai-Sheng Yang, MD, Jen-Shi Chen, MD, John Wen-Cheng Chang, MD, Yung-Chang Lin, MD, Kuang-Hui Yu, MD, Chang-Fu Kuo, MD, and Lai-Chu See, PhD

Abstract: Data from preclinical studies suggest that ursodeoxycholic acid (UDCA) has a chemopreventive effect on colorectal cancer (CRC) development, but no large observational study has examined this possibility. The aim of this study was to investigate the association of UDCA use with CRC risk in a nationwide population-based cohort. This nationwide population-based cohort study used data from the Taiwan National Health Insurance Research Database for the period from 2000 through 2010. This study included data from 7119 Taiwanese adults who received ≥28 cumulative defined daily doses (cDDDs) of UDCA and 14,238 patients who did not receive UDCA (<28 cDDDs). UDCA nonusers were matched 1:2 for age, sex, enrollment date, and presence of chronic liver disease, viral hepatitis, cholelithiasis, and alcoholic liver disease. The 2 cohorts were followed until December 31, 2010 or occurrence of CRC. Cox proportional hazards regression with robust Sandwich variance estimator, which can cooperate with matching design, was used to examine the association between UDCA use and CRC risk.

During 109,312 person-years of follow-up (median, 5 years), 121 patients had newly diagnosed CRC: 28 UDCA users (76.7 per 100,000 person-years) and 93 nonusers (127.7 per 100,000 person-years) (log-rank test: P = 0.0169). After multivariate adjustment for age, UDCA use was associated with a reduced risk of CRC (hazard ratio, 0.60; 95% confidence interval [CI], 0.39–0.92). The adjusted hazard ratios were 0.55 (95% CI, 0.35–0.89), 0.89 (95% CI, 0.36–2.20), and 0.63 (95% CI, 0.16–2.53) for patients with 28 to 180, 181 to 365, and >365 cDDDs, respectively, relative to nonusers. UDCA use was associated with reduced risk of CRC in a cohort mainly comprising patients with chronic liver diseases. However, further studies are needed to determine the optimal dosage of UDCA.

INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and fourth leading cause of cancer-related death globally. 1 Although recent advances in screening and treatment have improved CRC survival, the increasing incidence rate of CRC in Asian countries is a major challenge. 2 In Taiwan, CRC is the most common cancer and the third leading cause of cancer-related death. In 2012, there were an estimated 14,965 new CRC cases and 5313 deaths owing to CRC. 3

CRC development is a multistep process that can take several decades; thus, chemoprevention is a promising strategy for reducing CRC incidence. 4 Epidemiologic studies and clinical trials have shown that aspirin decreases CRC incidence. 5,6 Other agents, including non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), folic acid, calcium, vitamin D, and antioxidants, have been studied, but their effect on CRC incidence has not been determined because of heterogeneity in the populations studied and insufficient duration of follow-up. 7

Ursodeoxycholic acid (UDCA) is a synthetic bile acid extensively used in the treatment of primary sclerosing cholangitis, primary biliary cirrhosis, and other chronic cholestatic...
liver diseases. UDCA had a chemopreventive effect on colon cancer development in preclinical studies.\(^8\)\(^–\)\(^11\) On the basis of those experimental observations, the use of UDCA as a chemoprevention agent has been investigated in diverse populations at risk of CRC, including patients with a history of adenoma removal,\(^12\)\(^–\)\(^14\) familial adenomatous polypl,\(^15\) and inflammatory bowel disease.\(^16\)\(^–\)\(^21\) The conflicting results of those studies were attributed to differences in UDCA dosing, the small numbers of patients analyzed, methodologic differences between prospective and retrospective studies, and the high proportions of patients excluded from analysis.\(^22\)\(^–\)\(^23\) No large-scale epidemiologic studies have investigated this issue.

In Taiwan, which has a population of 23 million, chronic liver disease is a major health problem. The carrier rate of HBsAg in general population has been reported as high as 10%\(^.\)\(^24\)\(^–\)\(^26\) The prevalence rate of hepatitis C in general population was 4.5% in a community-based screening program during 1996 to 2005.\(^26\) One study using back-projection approach estimated that the prevalence rate of hepatitis C in 2012 was 2.8%.\(^27\) To delay development of sequelae such as cirrhosis and hepatocellular carcinoma, several hepatoprotectants, including silymarin and UDCA, are commonly prescribed for patients with chronic liver disease.\(^28\)\(^–\)\(^29\) The high incidence of CRC and common use of UDCA in Taiwan provide a unique opportunity to investigate the association between UDCA use and CRC development. We conducted a nationwide population-based cohort study to compare the risk of CRC development in UDCA users and nonusers.

**METHODS**

**Data Sources**

Taiwan began providing compulsory universal health insurance through a national health insurance (NHI) program in 1995. About 22.6 million of Taiwan’s 22.96 million people (98% of the total population) were enrolled for some form of health care coverage. The National Health Insurance Administration (NHIA) cooperates with the National Health Research Institute (NHRI) in storing and managing all insurance claims data in the National Health Insurance Research Databases (NHIRDs). The databases comprise of comprehensive information, including birth date, sex, diagnostic codes, surgery or procedures received, medications prescribed, admission date, hospitalizations, discharge date, medical institution codes, and expenditure amounts. In the years 2000 and 2005, the NHRI randomly sampled 1,000,000 patients registered in the NHI, to create the Longitudinal Health Insurance Database (LHID) 2000 and 2005, respectively. There were no statistically significant differences in age, sex, or health care costs between the 2 study groups in univariate analysis. The Kaplan–Meier method was used to determine eligibility for exemption from all copayments.

**Ascertainment of UDCA Use**

Information on all UDCA prescriptions was extracted from the NHRI prescription database. The date of prescription, daily dose, and number of days supplied were collected. Defined daily doses (DDDs) were used in the analysis, as recommended by the World Health Organization.\(^29\) According to the Anatomical Therapeutic Chemical Classification system (ATC)/DDD Index, the DDD of UDCA is 750 mg/day.\(^30\) To indicate duration of UDCA use, cumulative DDD (cDDD) was computed as the sum of dispensed DDD. Patients were categorized into 4 groups by number of cDDDs <28, 28–180, 181–365, >365 to examine the dose–response relationship, and patients who received UDCA for >28 cDDDs were defined as UDCA users.

**Ascertainment of CRC**

CRC events were identified using codes 153 and 154 of the ICD-9-CM. CRC diagnoses were verified by using records in the registry of catastrophic illnesses. In Taiwan, registration of CRC as a catastrophic illness is approved after evaluating pathologic and/or cytologic evidence, and a comprehensive review is conducted to determine eligibility for exemption from all copayments.

**Potential Confounders**

Comorbidities associated with CRC development included hypertension (ICD-9 codes 401–404), hyperlipidemia (ICD-9 code 272), diabetes mellitus (DM) (ICD-9 code 250), cardiovascular disease (ICD-9 codes 410–414), and heart failure (ICD-9 code 428) (32–34). We also assessed prescriptions >28 days for aspirin, NSAIDs (diclofenac, sulindac, indomethacin, acetamin, aceclofenac, meloxicam, ibuprofen, naproxen, ketoprofen, and mfenamic acid), and statins (atorvastatin, rosuvastatin, lovastatin, simvastatin, pravastatin, and fluvastatin), which could potentially confound the association between UDCA and CRC risk.\(^31\)\(^–\)\(^36\) Given lower gastrointestinal endoscopy (LGI) procedure could be a major confounding variable to detect CRC, patients who underwent LGI with or without biopsy and/or polypectomy were analyzed.

**Statistical Analysis**

The \(\chi^2\) test or unpaired \(t\) test was used to compare data between the 2 study groups in univariate analysis. The Kaplan–Meier method was used to estimate the time-to-event curve. Survival analysis (log-rank test in univariate analysis and a time-dependent Cox proportional hazards model in multivariate analysis) was used to compare the risk of CRC development in UDCA users and nonusers.
analysis with robust Sandwich variance estimator, which can deal with matching data)\textsuperscript{37} was used to examine the effect of UDCA on CRC prevention. Forward selection from variables significant in univariate analysis was used to determine the final Cox model. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated afterward. A 2-sided $P$ value of <0.05 was considered to indicate statistical significance. All analyses were performed using SAS statistical software (version 9.3; SAS Institute, Cary, NC).

RESULTS

We identified 7119 UDCA users ($\geq$28 cDDDs) and 14,238 nonusers (Figure 1). The demographic characteristics, comorbidities, and medication use of the patients are presented in Table 1. Overall, mean age was 54 years and 60% of patients were men. Chronic liver diseases were common (78%), followed by cholelithiasis (24%), hepatitis B or C (20%), and alcoholic liver disease (10%). The median follow-up time was 5 years. Because of the matched design, age, sex, the prevalence of the above liver disorders, and follow-up time were comparable between the 2 study groups. Hypertension, hyperlipidemia, DM, and cardiovascular disease were also common in the 2 study groups (prevalence, 10%–50%). The prevalence of hypertension, DM, cardiovascular diseases, and heart failure significantly differed between the 2 groups. NSAIDs had been prescribed for about half of the patients, aspirin for 20%, and statins for 13% to 16% of the patients. There was no significant difference in the rates of NSAID and aspirin prescriptions between the 2 groups. UDCA users had undergone more LGI examinations (3.06% vs 2.13%, $P < 0.001$), whereas no significant difference in terms of biopsy and polypectomy (0.94% vs 0.74%, $P < 0.1307$) was seen.

During 109,312 person-years of follow-up, 121 patients developed CRC (110.7 per 100,000 person-years): 28 UDCA users and 93 nonusers (CRC incidence rate per 100,000 person-years, 76.7 and 127.7, respectively; Table 1). UDCA users had a significantly higher CRC-free rate than did nonusers (log-rank test, $P = 0.0169$; Figure 2).

The unadjusted HR for development of CRC was 0.60 (95% CI, 0.39–0.92) among UDCA users as compared with nonusers. Age, hypertension, DM, and cardiovascular disease were also significantly associated with CRC incidence. The Cox

---

**FIGURE 1.** Study flowchart. cDDDs = cumulative defined daily doses, CRC = colorectal cancer, LHID = longitudinal health insurance database, UDCA = ursodeoxycholic acid.
proportional hazards model showed that age and UDCA use were associated with CRC incidence. The HR among UDCA users was 0.60 (95% CI, 0.39–0.92; Table 2).

We then explored the dose–response relationship among UDCA users. As compared with nonusers, UDCA users with a cDDD between 28 and 180 had the lowest age-adjusted HR (0.55; 95% CI, 0.35–0.89), followed by UDCA users with a cDDD of >365 (age-adjusted HR, 0.63; 95% CI, 0.16–2.53), and UDCA users with a cDDD between 181 and 365 (age-adjusted HR, 0.89; 95% CI, 0.36–2.20) (Table 3).

Because the subjects were predominantly patients with chronic hepatitis—among whom the risk of developing hepatocellular carcinoma and intrahepatic cholangiocarcinoma (HCC/ICC) is higher than in the general population38–40—competing risks might be a concern. To examine this possibility, we excluded UDCA users (n = 660) and their matched nonusers (n = 1320) who had received a diagnosis of primary liver cancer (ICD-9 codes 155.0 and 155.1) before or after the enrollment dates. The remaining numbers of UDCA users and nonusers were 6459 and 12,918, respectively. The CRC incidence rates of these 2 groups were similar to those in the main analysis, and UDCA use remained significant in multivariate analysis (adjusted HR, 0.58; 95% CI, 0.37–0.91; Table 3).

**DISCUSSION**

To our knowledge, this is the first population-based study of the association of UDCA use with the risk of CRC development. We found that, after age adjustment, CRC risk was 41% lower for UDCA users than for nonusers. We did not observe a dose–response relationship in CRC risk reduction with increasing cumulative UDCA dose.

| TABLE 1. Demographics, Comorbidities, and Medication Use Among UDCA Users and Matched Nonusers |
|-----------------------------------------------|---------------|---------------|---------------|
| UDCA Users (n = 7119)                      | Matched Nonusers (n = 14238) |
| n                | %                | n                | %                | P    |
| Age, y          |                  |                  |                  |      |
| 20–49           | 2651             | 37.24            | 5307             | 37.27 | 0.9969* |
| 50–64           | 2557             | 35.92            | 5116             | 35.93 |      |
| 65+             | 1911             | 26.84            | 3815             | 26.79 |      |
| Mean ± sd       | 54.80 ± 14.80    | 54.79 ± 14.79    | 0.9667†          |      |
| Sex             |                  |                  |                  |      |
| Female          | 2800             | 39.33            | 5600             | 39.33 | 1.0000* |
| Male            | 4319             | 60.67            | 8638             | 60.67 |      |
| Comorbidity     |                  |                  |                  |      |
| Chronic liver disease | 5538             | 77.79            | 11076            | 77.79 | 1.0000* |
| Hepatitis A     | 5                | 0.7             | 10               | 0.7    | 1.0000* |
| Hepatitis B     | 1480             | 20.79            | 2960             | 20.79 | 1.0000* |
| Hepatitis C     | 1469             | 20.63            | 2938             | 20.63 | 1.0000* |
| Cholelithiasis  | 1716             | 24.10            | 3432             | 24.10 | 1.0000* |
| Alcoholic liver disease | 716               | 10.06            | 1432             | 10.06 | 1.0000* |
| Hypertension    | 3537             | 49.68            | 6650             | 46.71 | <0.0001* |
| Diabetes mellitus | 2501            | 35.13            | 4140             | 29.08 | <0.0001* |
| Hyperlipidemia  | 3004             | 42.20            | 5876             | 41.27 | 0.1950† |
| Cardiovascular disease | 1901          | 26.70            | 4170             | 29.29 | <0.0001* |
| Heart failure   | 450              | 6.32             | 791              | 5.56  | 0.0242† |
| Medication use  |                  |                  |                  |      |
| Aspirin         | 1392             | 19.55            | 2810             | 19.74 | 0.7517† |
| NSAIDs          | 4031             | 56.62            | 8042             | 56.48 | 0.8452* |
| Statin          | 1153             | 16.20            | 1876             | 13.18 | <0.0001* |
| LGIE            |                  |                  |                  |      |
| Colonoscopy, sigmoidoscopy, and rectoscopy examinations | 218              | 3.06             | 303              | 2.13  | <0.0001* |
| Biopsy and polypectomy | 67              | 0.94             | 106              | 0.74  | 0.1307* |
| Follow-up years (median) | 5.013          | 5.005            | 5.005            | 5.005 |      |
| Number of CRC   | 28               | 93               | 28               | 28     |      |
| Sum of person-years | 36488.0       | 72823.9          | 101.8–153.7      | 101.8–153.7      |      |
| Incidence of CRC | 76.7            | 127.7            |                  |      |
| 95% CI          | 48.3–105.2       | 101.8–153.7      |                  |      |

CI = confidence interval, LGIE = lower gastrointestinal examinations, NSAID = nonsteroidal anti-inflammatory drugs, UDCA = ursodeoxycholic acid.

* Chi-squared test.
† Independent t test.
‡ incidence per 100,000 person-years.
FIGURE 2. Kaplan–Meier curves of event-free probability for colorectal cancer (CRC) among UDCA users and nonusers (n = 21,357) (P = 0.0169 by log-rank test).

TABLE 2. Univariate and Multivariate Cox Proportional Hazard Analyses (With Sandwich Variance Estimator) for Developing Colorectal Cancer

|                     | Univariate                  | Multivariate             |
|---------------------|-----------------------------|--------------------------|
|                     | HR (95% CI)                 | P                        |
|                     |                             | 1.00 (Reference)         |
| Age, y<sup>1</sup>  |                             |                          |
| 20–49               | 1.00 (Reference)            | <0.0001                  |
| 50–64               | 12.66 (3.93–40.71)          | <0.0001                  |
| ≥65                 | 25.12 (7.94–79.55)          | <0.0001                  |
| Sex                 |                             |                          |
| Female              | 1.00 (Reference)            | 1.00 (Reference)         |
| Male                | 1.23 (0.85–1.79)            | 25.14 (7.94–79.59)       |
| Comorbidity<sup>1</sup> |                             |                          |
| Chronic liver disease | 0.66 (0.43–1.02)         | 0.0584                   |
| Hepatitis A         | ---                         | ---                      |
| Hepatitis B         | 0.55 (0.26–1.18)           | 0.1224                   |
| Hepatitis C         | 0.68 (0.33–1.39)           | 0.2911                   |
| Cholelithiasis      | 0.98 (0.55–1.74)           | 0.9402                   |
| Alcoholic liver disease | 0.82 (0.34–2.02) | 0.6697                   |
| Hypertension        | 2.76 (1.84–4.15)           | <0.0001                  |
| Diabetes mellitus   | 1.72 (1.21–2.46)           | 0.0026                   |
| Hyperlipidemia      | 1.25 (0.88–1.78)           | 0.2152                   |
| Cardiovascular disease | 1.70 (1.18–2.44)   | 0.0042                   |
| Heart failure       | 1.29 (0.69–2.40)           | 0.4277                   |
| Medication use      |                             |                          |
| UDCA                | 0.60 (0.39–0.92)           | 0.0185                   |
| Aspirin             | 1.39 (0.93–2.08)           | 0.1089                   |
| NSAIDs              | 0.99 (0.69–1.41)           | 0.9412                   |
| Statin              | 1.10 (0.72–1.68)           | 0.6715                   |
| LGIE                |                             |                          |
| Colonoscopy, sigmoidoscopy, and rectoscopy examinations | 0.76 (0.19–3.09) | 0.7057 |
| Biopsy and polypectomy | 1.25 (0.18–9.00) | 0.8222 |

CI = confidence interval, HR = hazard ratio, LGIE = lower gastrointestinal examinations, NSAID = nonsteroidal anti-inflammatory drugs, UDCA = ursodeoxycholic acid.

<sup>1</sup>Final model was determined using forward selection.

<sup>1</sup>Time-dependent.
The dose and duration of UDCA use required for chemoprevention has not been carefully studied. In a randomized controlled study, UDCA use (8–10 mg/kg/day) for 3 years did not decrease the overall rate of adenoma recurrence among 1285 patients who had undergone adenoma removal. Another prospective study of UDCA 750 mg/day in 20 patients with colorectal adenoma found no difference in the rate of colorectal mucosal proliferation, as compared with placebo, during a relatively short follow-up period of 6 months. In a retrospective analysis of 59 patients with ulcerative colitis and primary sclerosing cholangitis, UDCA 9 to 10 mg/kg/day for a mean duration of 3.5 years significantly decreased the risk of colonic dysplasia. Two retrospective studies investigated standard UDCA dosages (13–15 mg/kg/day)—one in 116 patients with primary biliary cirrhosis who had undergone adenoma removal, the other in 52 patients with ulcerative colitis and primary sclerosing cholangitis. The first study found that standard UDCA dosages (mean duration of administration, 45 months) had beneficial effects on colorectal dysplasia. The second study reported a similar beneficial effect on colorectal dysplasia with a mean follow-up of 42 months. Higher UDCA dosages (28–30 mg/kg/day) were associated with increased risk of colorectal neoplasia in a retrospective analysis of 56 patients with ulcerative colitis and primary sclerosing cholangitis. However, the increase in risk was not significant when patients with possible adenoma-like lesions were excluded from the analysis. Another study showed that high UDCA doses (17–23 mg/kg/day) had no significant effect on CRC or dysplasia in patients with ulcerative colitis and primary sclerosing cholangitis.

The above-mentioned studies were conducted in high-risk populations, such as patients with a history of adenoma removal and ulcerative colitis. The results of these studies thus cannot be generalized to general populations. In the present study, we investigated the chemopreventive effect of UDCA in a cohort mainly with chronic liver diseases and no excess risk of CRC, and DDD was used to estimate UDCA use. The DDD of UDCA is 750 mg; therefore, the estimated daily dose is about 10 to 15 mg/kg. We found that a cDDD between 28 and 180 (the cDDD for most of the patients receiving UDCA) was inversely associated with CRC incidence. Although there was a trend toward risk reduction among patients with >180 cDDDs, the decrease was not significant, probably because of the small number of users at these dose levels.

Most of the present patients had chronic liver disease, which is associated with a high risk of HCC/ICC. Survival is commonly short among patients with HCC/ICC, and thus they may not have time to develop CRC. Such competing risks could affect the results. We attempted to address this competing risk bias by conducting analysis that excluded UDCA users and nonusers with primary liver cancer before or after the enrollment dates. The risk of developing CRC remained lower in users than in nonusers, which indicates that primary liver cancer did not influence the association between UDCA use and CRC risk.

Patients with increasing frequency of medical checkup are more likely to take LGI examinations, which might facilitate the detection of CRC. Our findings found UDCA users indeed had more LGI examinations than nonusers while these procedures were not associated with increased risk of CRC.

The mechanisms by which UDCA use may decrease CRC risk are not well understood. UDCA administration significantly reduced the number of tumor-bearing rats and inhibited tumor development in a rodent model of azoxymethane-induced colon cancer. Findings from this azoxymethane model suggest several mechanisms for the effect of UDCA, including suppression of cyclooxygenase-2 through both p21K-ras-dependent and -independent pathways, inhibition of epidermal growth factor receptor signaling, reduction of toxic secondary bile acid levels, and upregulation of E-cadherin expression.

This study has several strengths. First, the study population was selected by using a computerized database and is therefore highly representative. Moreover, selection bias is unlikely. UDCA nonusers were matched for presence of chronic liver disease, viral hepatitis, and cholelithiasis, as these are common reasons for prescribing UDCA. Therefore, heterogeneity between the user and nonuser groups was reduced. Finally, because data on UDCA use were obtained from a historical database that includes all prescription information before the date of CRC diagnosis, the possibility of recall bias can be excluded.

Several limitations of this study should be noted. First, we lacked detailed information on some risk factors such as...
inflammatory bowel disease, cigarette smoking, alcohol consumption, physical activity, body mass index, family CRC history. Second, the prescription did not guarantee drug compliance and anonymization of records impede us to contact patients directly. Third, underestimation of cumulative UDCA dose is likely because drug prescription data before 1996 was not available. To minimize the possible bias, we only included patients who were first prescribed UDCA after 2000. That means that the user group had no history of UDCA prescription for 4 years before starting the study. Fourth, relatively small sample size did not allow us to further examine the effect of UDCA on site-specific CRC. Finally, unmeasured factors that differ between the 2 study groups might be existed.

In conclusion, this population-based study indicates that UDCA use was associated with a 41% reduction in CRC risk in a cohort mainly comprising patients with chronic liver diseases. This suggests that UDCA might have a role in CRC chemoprevention. Prospective studies are needed to confirm these results and determine optimal dosing and duration of treatment.

REFERENCES

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907.
3. Taiwan Cancer Registry. 2012. (Accessed October 23, 2014. Available at: http://www.doh.gov.tw/EN2006/DM/DM2.aspx?now_fod_list_no=12402&class_no=390&level_no=2).
4. Fajardo AM, Piazza GA. Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. An J Physiol Gastrointest Liver Physiol. 2015;309:G59–G70.
5. Dube’ C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146:365–375.
6. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–1750.
7. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2010;14:1–206.
8. Earnest DL, Holubec H, Wali RK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994;54:5071–5074.
9. Jacoby RF, Cole CE, Hawk ET, et al. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroentrology. 2004;127:838–844.
10. Khare S, Mustafi R, Cerda S, et al. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/ enhancer-binding protein. Nutr Cancer. 2008;60:389–400.
11. Kohno H, Suzuki R, Yasui Y, et al. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res. 2007;13:2519–2525.
12. Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology. 2003;38:203–209.
13. Alberts DS, Martinez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst. 2005;97:846–853.
14. Ochsenkuhn T, Marsteller I, Hay U, et al. Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study. Digestion. 2003;68:209–216.
15. Parc Y, Desaint B, Flejou JF, et al. The effect of ursodeoxycholic acid on duodenal adenomas in familial adenomatous polyposis: a prospective randomized placebo-control trial. Colorectal Dis. 2012;14:854–860.
16. Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106:1638–1645.
17. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–983.
18. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colon neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89–95.
19. Sjoqvist U, Tribukait B, Ost A, et al. Ursodeoxycholic acid treatment in IBD-patients with colocolitis dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res. 2004;24:3121–3127.
20. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;22:783–788.
21. Lindstrom L, Boberg KM, Wikman O, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther. 2012;35:451–457.
22. Serfaty L. Chemoprevention of colorectal cancer with ursodeoxycholic acid: prov. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S53–60.
23. Carey EJ, Lindor KD. Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S61–64.
24. Lin DB, Wang HM, Lee YL, et al. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine. 1998;16:1683–1687.
25. Ni YH, Chang MH, Huang LM, et al. Hepatitis B Virus Infection and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Reg Issues. 2014;3:5–11.
26. Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106:148–155.
27. McEwan P, Ward T, Chen CI, et al. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Reg Issues. 2014;3:5–11.
28. Chen TJ, Chou LF, Hwang SI. Utilization of hepatoprotectants within the National Health Insurance in Taiwan. J Gastroenterol Hepatol. 2003;18:868–872.
29. WHO, Collaborating Center for Drugs Statistics, Methodology. ATC Index with DDDs 2003. Oslo: WHO: Oslo; 2003.
30. ATC/DDD Index. 2014. (Accessed September 29, 2015. Available at: http://www.whocc.no/atc_ddd_index/?code=A05AA02.).
32. Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106:1911–1921quiz 22.

33. Jinjuvadia R, Lohia P, Jinjuvadia C, et al. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol. 2013;47:33–44.

34. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–2192.

35. Simon MS, Rosenberg CA, Rodabough RJ, et al. Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol. 2012;22:17–27.

36. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914–923.

37. Wang CY. Robust sandwich covariance estimation for regression calibration estimator in Cox regression with measurement error. Stat Probabil Lett. 1999;45:371–378.

38. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.

39. Zhou Y, Zhao Y, Li B, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012;12:289.

40. Chang JS, Tsai CR, Chen LT. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PLoS One. 2013;8:e69981.

41. Wali RK, Stoiber D, Nguyen L, et al. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev. 2002;11:1316–1321.

42. Khare S, Cerda S, Wali RK, et al. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res. 2003;63:3517–3523.

43. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Natl 2004;134:483–486.

44. Feldman R, Martinez JD. Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta. 2009;1793:1387–1394.

45. Batta AK, Salen G, Holubec H, et al. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res. 1998;58:1684–1687.

46. Wali RK, Khare S, Tretiakova M, et al. Ursodeoxycholic Acid and F6-D3 Inhibit Aberrant Crypt Proliferation in the Rat Azoxymethane Model of Colon Cancer Roles of Cyclin D1 and E-Cadherin. Cancer Epidemiol Biomarkers Prev. 2002;11:1653–1662.